Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors

Biology of Reproduction

Volumn 89, Issue 5, 2013, Pages

  Wardell, Jennifer R ^a   Hodgkinson, Kendra M ^c   Binder, April K ^d   Seymour, Kimberly A ^b   Korach, Kenneth S ^d   Vanderhyden, Barbara C ^c   Freiman, Richard N ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Estradiol estradiol receptor; Ovarian cancer; Ovary; Premature ovarian failure; TAF4B

Indexed keywords

DIETHYLSTILBESTROL DERIVATIVE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GENERAL TRANSCRIPTION FACTOR; MESSENGER RNA; TRANSCRIPTION FACTOR IID; TRANSCRIPTION FACTOR TAF4A; TRANSCRIPTION FACTOR TAF4B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; FEMALE; GRANULOSA CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; UPREGULATION;

ESTRADIOL/ESTRADIOL RECEPTOR; OVARIAN CANCER; OVARY; PREMATURE OVARIAN FAILURE; TAF4B;

ANIMALS; CELLS, CULTURED; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID;

EID: 84898732505     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.113.111336     Document Type: Article

References (48)

1. Edson MA, Nagaraja AK, Matzuk MM. The mammalian ovary from genesis to revelation. Endocr Rev 2009; 30:624-712.
2. Fowler PA, Bellingham M, Sinclair KD, Evans NP, Pocar P, Fischer B, Schaedlich K, Schmidt JS, Amezaga MR, Bhattacharya S, Rhind SM, O'Shaughnessy PJ. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health. Mol Cell Endocrinol 2012; 355:231-239.
3. Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008; 11:301-321.
4. Infertility FastStats [Internet]. Atlanta, GA: Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/fertile.htm. Accessed 13 August 2013.
5. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376:911-921.
6. Brosens IA, Koninckx PR, Corveleyn PA. A study of plasma progesterone, oestradiol-17beta, prolactin and LH levels, and of the luteal phase appearance of the ovaries in patients with endometriosis and infertility. Br J Obstet Gynaecol 1978; 85:246-250.
7. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
8. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992; 75:1497-1502.
9. Park SH, Kim KY, An BS, Choi JH, Jeung EB, Leung PC, Choi KC. Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. J Reprod Dev 2009; 55:23-29.
10. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002; 94:617-629.
11. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 2009; 15:2971-2978.
12. Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC. 17beta-Estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 2010; 151:929-938.
13. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002; 156:363-373.
14. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92:472-479.
15. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288:334-341.
16. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290:1739-1748.
17. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710.
18. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285:1460-1465.
19. Drummond AE, Fuller PJ. Ovarian actions of estrogen receptor-beta: an update. Semin Reprod Med 2012; 30:32-38.
20. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and what are their targets? Physiol Rev 2007; 87:905-931.
21. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833-842
22. Nagai MA, Brentani MM. Gene expression profiles in breast cancer to identify estrogen receptor target genes. Mini Rev Med Chem 2008; 8: 448-454.
23. Knauff EA, Franke L, van Es MA, van den Berg LH, van der Schouw YT, Laven JS, Lambalk CB, Hoek A, Goverde AJ, Christin-Maitre S, Hsueh AJ, Wijmenga C, et al. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod 2009; 24:2372-2378.
24. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-615.
25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-404.
26. Freiman RN, Albright SR, Zheng S, Sha WC, Hammer RE, Tjian R. Requirement of tissue-selective TBP-associated factor TAFII105 in ovarian development. Science 2001; 293:2084-2087.
27. Lovasco LA, Seymour KA, Zafra K, O'Brien CW, Schorl C, Freiman RN. Accelerated ovarian aging in the absence of the transcription regulator TAF4B in mice. Biol Reprod 2010; 82:23-34.
28. Voronina E, Lovasco LA, Gyuris A, Baumgartner RA, Parlow AF, Freiman RN. Ovarian granulosa cell survival and proliferation requires the gonad-selective TFIID subunit TAF4b. Dev Biol 2007; 303:715-726.
29. Tinnanooru P, Dang VH, Nguyen TH, Lee GS, Choi KC, Jeung EB. Estrogen regulates the localization and expression of calbindin-D9k in the pituitary gland of immature male rats via the ERalpha-pathway. Mol Cell Endocrinol 2008; 285:26-33.
30. Sinkevicius KW, Burdette JE, Woloszyn K, Hewitt SC, Hamilton K, Sugg SL, Temple KA, Wondisford FE, Korach KS, Woodruff TK, Greene GL. An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 2008; 149:2970-2979.
31. Rilianawati, Rahman NA, Huhtaniemi I. Hormonal regulation of proliferation of granulosa and Leydig cell lines derived from gonadal tumors of transgenic mice expressing the inhibin-alpha subunit promoter/ simian virus 40 T-antigen fusion gene. Mol Cell Endocrinol 1999; 149(1-2):9-17.
32. Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. FASEB J 2010; 24:4660-4667.
33. Binder AK, Rodriguez KF, Hamilton KJ, Stockton PS, Reed CE, Korach KS. The absence of ER-beta results in altered gene expression in ovarian granulosa cells isolated from in vivo preovulatory follicles. Endocrinology 2013; 154:2174-2187.
34. Binder AK, Burns KA, Rodriguez KF, Korach KS. Aberrant expression of Dmrt1 and Foxl2 in transdifferentiated Sertoli-like cells in the ovaries of Ex3abERKO double knockout mice. In: Supplement to Biology of Reproduction for the 45th Annual Meeting of the Society for the Study of Reproduction and the 18th Ovarian Workshop, August 12-15, 2012, State College, Pennsylvania. Biol Reprod 2012; suppl: Abstract 529.
35. Folmar LC, Hemmer M, Denslow ND, Kroll K, Chen J, Cheek A, Richman H, Meredith H, Grau EG. A comparison of the estrogenic potencies of estradiol, ethynylestradiol, diethylstilbestrol, nonylphenol and methoxychlor in vivo and in vitro. Aquat Toxicol 2002; 60:101-110.
36. Miller BG, Armstrong DT. Effects of a superovulatory dose of pregnant mare serum gonadotropin on ovarian function, serum estradiol, and progesterone levels and early embryo development in immature rats. Biol Reprod 1981; 25:261-271.
37. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 2011; 25:1527-1538.
38. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 2004; 145:3473-3486.
39. Binder AK, Burns AB, Rodriguez KF, Korach KS. Abnormal appearance and function of ovaries from Ex3alphabeta estrogen receptor double knockout animals. In: Supplement to Biology of Reproduction for the 44th Annual Meeting of the Society for the Study of Reproduction, July 31 through August 4, 2011, Portland, Oregon. Biol Reprod 2011; suppl: Abstract 704.
40. Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol 2012; 5: e8.
41. Sar M, Welsch F. Differential expression of estrogen receptor-beta and estrogen receptor-alpha in the rat ovary. Endocrinology 1999; 140: 963-971.
42. Driscoll MD, Sathya G, Muyan M, Klinge CM, Hilf R, Bambara RA. Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 1998; 273:29321-29330.
43. Petz LN, Nardulli AM. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 2000; 14:972-985.
44. Liu WL, Coleman RA, Grob P, King DS, Florens L, Washburn MP, Geles KG, Yang JL, Ramey V, Nogales E, Tjian R. Structural changes in TAF4b-TFIID correlate with promoter selectivity. Mol Cell 2008; 29: 81-91.
45. Geles KG, Freiman RN, Liu WL, Zheng S, Voronina E, Tjian R. Celltype-selective induction of c-jun by TAF4b directs ovarian-specific transcription networks. Proc Natl Acad Sci U S A 2006; 103:2594-2599.
46. Falender AE, Shimada M, Lo YK, Richards JS. TAF4b, a TBP associated factor, is required for oocyte development and function. Dev Biol 2005; 288:405-419.
47. Yamit-Hezi A, Dikstein R. TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB. EMBO J 1998; 17:5161-5169.
48. Haring J, Schuler S, Lattrich C, Ortmann O, Treeck O. Role of estrogen receptor beta in gynecological cancer. Gynecol Oncol 2012; 127:673-676.